GlassScriptPhysician profile
Allan James White
NPI 1497782114
$5,393.68
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $438 · 2021: $1,010 · 2022: $1,023 · 2023: $1,361 · 2024: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $977.22 | 2019-2024 | Lynparza, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $611.48 | 2019-2024 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $299.30 | 2021-2024 | Shingrix, Zejula, Ojjaara |
| Incyte Corporation | $255.99 | 2021-2024 | Jakafi, Monjuvi |
| Karyopharm Therapeutics INC. | $236.34 | 2021-2023 | Xpovio |
| Genzyme Corporation | $213.86 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.72 | 2020-2024 | Iclusig, Ninlaro, Alunbrig |
| Myriad Genetic Laboratories, INC. | $193.97 | 2021-2023 | Precisetumor |
| Seagen INC. | $187.88 | 2019-2023 | Tivdak, Adcetris |
| Amgen INC. | $168.78 | 2020-2022 | |
| Clovis Oncology, INC. | $167.42 | 2019-2021 | |
| Eisai INC. | $147.70 | 2019-2024 | |
| Daiichi Sankyo INC. | $144.58 | 2020-2023 | Injectafer |
| Genentech USA, INC. | $126.37 | 2019-2024 | Gazyva, Polivy, Lunsumio |
| Janssen Biotech, INC. | $124.18 | 2020-2024 | Tecvayli, Imbruvica, Darzalex |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.